CN104098143B - Multifunctional single-phase nano material - Google Patents
Multifunctional single-phase nano material Download PDFInfo
- Publication number
- CN104098143B CN104098143B CN201410370584.1A CN201410370584A CN104098143B CN 104098143 B CN104098143 B CN 104098143B CN 201410370584 A CN201410370584 A CN 201410370584A CN 104098143 B CN104098143 B CN 104098143B
- Authority
- CN
- China
- Prior art keywords
- nano material
- single phase
- phase nano
- powder
- magnetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention provides a kind of single phase nano material, be specifically related to a kind of Multifunctional single-phase nano material for realizing biomedical magnetic targeted, diagnosis, treatment integration, it has magnetic, photoluminescence, ultrasonic response, visible light-responded and biocompatibility simultaneously.
Description
Technical field
The present invention relates to a kind of Multifunctional single-phase nano material with magnetic, luminescence, ultrasonic response, visible light-responded and biocompatibility, be expected to realize biomedical magnetic targeted, diagnosis, treatment integration, belong to multifunctional material, material and life science crossing domain.
Background technology
Target, imaging, diagnosis, treatment are integrally conducive to early diagnosis and treat in time, this to the health of the mankind and Sustainable development also very important, and find the core place that a kind of biocompatible materials gathered multi-function in integral whole is this research.In recent years, inorganic nano material is widely used in biomedical sector, as cellular segregation, pharmaceutical carrier, magnetic fluorescence probe, mark, image-forming diagnose, treatment etc., but these materials are often confined to single function, difunctional and multi-functional extremely rare.In order to realize multifunctional all, current researchist is mostly by preparing the modes such as nucleocapsid structure the Material cladding of several difference in functionality, but often preparation process is complicated, and material is unstable, and result still can not meet actual needs.
Can realize biomedical magnetic targeted, diagnosis, treatment integration material should the characteristic such as integrated magnetic, luminescence, photoresponse.The magnetic of such as material can realize magnetic targeted and magnetic imaging diagnosis, ultrasonic response, luminescent properties, magnetic property combine, the multi-modal imaging diagnosed can be realized, like this can in conjunction with nuclear magnetic resonance high spatial resolution and the highly sensitive advantage of fluorescence imaging, and multiparameter imaging while of carrying out multiple physiological parameter or biochemical parameter, thus the identification strengthened pathology and diagnosis capability.Material, in the ultrasonic performance with decomposing organic matter under illumination, can be used for the treatment of disease, and in conjunction with imaging function, may be used for the interventional therapy that image guides, thus improves tolerance range and the success ratio of operation.
Material B i in the present invention
xer
yyb
zfe
2.75co
0.25ti
3o
21crystalline structure belongs to laminated perovskite structure.We are by design preparation method, make the particle of nanoscale, can by cytophagy, by elementary composition careful design, the element with different performance is embedded in same crystalline structure, thus magnetic, photoluminescence, ultrasonic response, visible light-respondedly combine in a monophase materials, thus make to realize target, imaging, diagnosis, treatment integration become possibility, this has far reaching significance to the development that material and life science are intersected.
Summary of the invention
In one aspect of the invention, provide a kind of single phase nano material, it consists of Bi
xer
yyb
zfe
2.75co
0.25ti
3o
21; Wherein
X=5.46-6.75, preferred 5.46-6, more preferably 5.46;
Y=0.05-1.4, preferred 0.2-1.4, more preferably 1.4;
Z=0.14-1.4, preferred 0.14-0.8, more preferably 0.14;
And x+y+z=7.
In one embodiment of the invention, the spacer of monophase materials is F2mm (42).
In one embodiment of the invention, single phase nano material of the present invention is the powder of nano-scale.
In one embodiment of the invention, the size of single phase nano material of the present invention refers to 10nm to 100nm, preferred 60nm to 100nm.
In one embodiment of the invention, single phase nano material of the present invention has magnetic.
In one embodiment of the invention, single phase nano material of the present invention launches ruddiness under infrared ray excited.
In one embodiment of the invention, single phase nano material of the present invention under visible light illumination and/or under hyperacoustic effect by organic substance decomposing.
In one embodiment of the invention, single phase nano material of the present invention can by cytophagy, and lifeless matter toxicity.
In one embodiment of the invention, single phase nano material of the present invention is used for the purposes of biomedical magnetic targeted or NMR (Nuclear Magnetic Resonance) imaging.
In one embodiment of the invention, single phase nano material of the present invention is used for the purposes of biomedical optical imaging and fluorescent probe.
In one embodiment of the invention, single phase nano material of the present invention is used for the purposes of biomedical light exposure treatment and ultrasound treatment.
In another aspect of the present invention, provide a kind of method preparing single phase nano material, described method comprises:
By Bi, Er, Yb, Fe, Co, Ti source compound in x: y: z: 2.75: 0.25: 3 ratio be jointly dissolved in after in solvent, with precipitant mix, form suspension, afterwards throw out washed, dry, calcining, obtain and consist of Bi
xer
yyb
zfe
2.75co
0.25ti
3o
21single phase nano material;
Wherein
X=5.46-6.75, preferred 5.46-6, more preferably 5.46;
Y=0.05-1.4, preferred 0.2-1.4, more preferably 1.4;
Z=0.14-1.4, preferred 0.14-0.8, more preferably 0.14;
And x+y+z=7.
In one embodiment of the invention, Bi, Er, Yb, Fe, Co, Ti source compound is the nitrate of above element, oxalate, Glacial acetic acid salt or oxide compound etc.
In one embodiment of the invention, use nitric acid etc. are as solvent.
In one embodiment of the invention, sodium hydroxide or potassium hydroxide etc. can be used as precipitation agent.
Accompanying drawing explanation
Fig. 1 is the single-phase Bi that inventive embodiments 5 obtains
5.46er
1.4yb
0.14fe
2.75co
0.25ti
3o
21the X-ray diffractogram of nano-powder;
Fig. 2 is the single-phase Bi that inventive embodiments 5 obtains
5.46er
1.4yb
0.14fe
2.75co
0.25ti
3o
21the scanning electron microscope diagram of nano-powder;
Fig. 3 is the single-phase Bi that inventive embodiments 5 obtains
5.46er
1.4yb
0.14fe
2.75co
0.25ti
3o
21the room temperature ferromagnetic performance test pattern of nano-powder;
Fig. 4 is the single-phase Bi that inventive embodiments 5 obtains
5.46er
1.4yb
0.14fe
2.75co
0.25ti
3o
21the visible light photocatalysis of nano-powder decomposes rhodamine B graphic representation;
The single-phase Bi that Fig. 5 inventive embodiments 5 is obtained
5.46er
1.4yb
0.14fe
2.75co
0.25ti
3o
21the 53KHz ultrasonic decomposition rhodamine B graphic representation of nano-powder;
The single-phase Bi that Fig. 6 inventive embodiments 5 is obtained
5.46er
1.4yb
0.14fe
2.75co
0.25ti
3o
21the luminous spectrogram that nano-powder 980nm excites;
The single-phase Bi that Fig. 7 inventive embodiments 5 is obtained
5.46er
1.4yb
0.14fe
2.75co
0.25ti
3o
21nano-powder and human body HeLa cell cultures 24 hours, imaging after fixing microscopy, and the powder dispersion of different concns is to the inhibiting rate of cell.
Embodiment
One embodiment of the invention provide a kind of Multifunctional single-phase nano material be expected to for biomedical magnetic targeted, diagnosis, treatment integration, and component is Bi
xer
yyb
zfe
2.75co
0.25ti
3o
21.
One embodiment of the invention can realize by the following method: by a step lead compound legal system for nano-powder, the simple cost of its preparation process is low, and the cycle is short.
The concrete steps of one embodiment of the invention are, by Bi, Fe, Yb, Fe, Co, Ti source compound by above-mentioned x: y: z: 2.75: 0.25: 3 (wherein x=5.46-6.75, y=0.05-1.4, z=0.14-1.4) ratio, jointly be dissolved in a kind of solvent and form homogeneous mixture solotion, mix with the alkaline solution of suitable concentration, reaction forms suspension again.After the time set ageing of solution, remove supernatant liquor, by deionized water and dehydrated alcohol repetitive scrubbing extremely neutrality, after dry, certain temperature calcines for some time.Ultrasonic disperse is in ethanol afterwards, gets homogeneous solution, obtains powder after evaporating solvent.
In one embodiment of the invention, the performance of product of the present invention can be measured in the following manner:
1. take a morsel powder, under normal temperature, uses vibrating sample magnetometer to survey its magnetic property;
2. getting quantitative powder is scattered in quantitative rhdamine B solution, under 20w fluorescent lamp (wavelength 400-720nm) irradiates, in certain hour, and the change of test rhdamine B strength of solution.
3. get quantitative powder to be scattered in quantitative rhdamine B solution, be placed in the ultrasonic wave of certain frequency and whole process lucifuge, in certain hour, the change of test rhdamine B strength of solution.
4. get quantitative powder, under 980nm laser, measure luminous spectrum.
5. the powder that takes a morsel dispersion in aqueous, cultivate together with specific human body cell, after 24 hours, fixing microscopy, under light field and under UV-light, observation imaging, cytophagy and bio-toxicity situation, and by fluorocyte activity monitor system test material to the inhibiting rate of cell metabolic activity.
The present invention is further illustrated below in conjunction with example.
Embodiment 1
(1) 0.704g tetrabutyl titanate is taken, 2.257g five nitric hydrate bismuths, 0.766g Fe(NO3)39H2O, 0.050g Cobaltous nitrate hexahydrate, 0.015g five nitric hydrate erbium, it be 5mL concentration is that in the nitric acid of 4M, magnetic agitation is metallic ion mixed liquor uniformly that 0.062g five nitric hydrate ytterbium is dissolved in volume.
Table 1:Bi
6.75er
0.05yb
0.2fe
2.75co
0.25ti
3o
21raw material
| Nomenclature of drug | Tetrabutyl titanate | Five nitric hydrate bismuths | Fe(NO3)39H2O |
| Take quality (g) | 0.704 | 2.257 | 0.766 |
| Nomenclature of drug | Cobaltous nitrate hexahydrate | Five nitric hydrate erbiums | Five nitric hydrate ytterbiums |
| Take quality (g) | 0.050 | 0.015 | 0.062 |
(2) be that the potassium hydroxide solution of 1.5M dropwise joins in above-mentioned metallic ion mixed liquor by 45mL concentration, whole process is all complete under magnetic stirring, forms uniform suspension.
(3), after suspension being left standstill 4 hours, supernatant liquor is removed, by deionized water and dehydrated alcohol repetitive scrubbing extremely neutrality, dry.
(4) powder 600 DEG C calcining 3 hours are obtained by above-mentioned.
(5) powder is placed in ethanolic soln ultrasonic, gets the solution that is uniformly dispersed, after evaporating solvent, obtain powder.
XRD result shows that sample is monophase materials, and PDF card sequence number is 54-1044, spacer F2mm (42); SEM result shows the morphology microstructure obtained to be diameter is the nanometer ball of about 60-100nm; Under powder room temperature, ferromagnetic property measures (magnetic hysteresis loop), under result shows normal temperature, and the magnetic that the display of this powder is very strong, residual magnetization 2M
r1.42emu/g.Visible light photocatalysis test result shows, irradiate within 4 hours, can degrade 75% rhodamine B.Ultrasonic degradation test result shows, within 4 hours, can degrade 82% rhodamine B.Glow under 980nm laser excitation.Powder dispersion soln and human body HeLa cell cultures 24 hours, result shows that nano particle can by cytophagy, and cell is intact, only has the inhibiting rate of 12%, illustrative material safety non-toxic under 200 μ g/mL.
Table 2:Bi
6.75er
0.05yb
0.2fe
2.75co
0.25ti
3o
21performance test data
| The phase composite of material thing | Single-phase, PDF card number: 54-1044 |
| Material particle size | 60-100nm |
| Residual magnetization (2M r) | 1.42emu/g |
| Visible light photocatalysis efficiency (4 hours) | 75％ |
| Ultrasonic degradation efficiency (4 hours) | 82％ |
| 980nm stimulated luminescence is composed | Ruddiness, maximum strength 8.98 × 10 4 |
| Inhibiting rate (200 μ g/mL24 hour) | 12％ |
Embodiment 2
(1) 0.714g tetrabutyl titanate is taken, 2.035g five nitric hydrate bismuths, 0.777g Fe(NO3)39H2O, 0.051g Cobaltous nitrate hexahydrate, 0.062g five nitric hydrate erbium, it be 5mL concentration is that in the nitric acid of 4M, magnetic agitation is metallic ion mixed liquor uniformly that 0.251g five nitric hydrate ytterbium is dissolved in volume.
Table 3:Bi
6er
0.2yb
0.8fe
2.75co
0.25ti
3o
21raw material
| Nomenclature of drug | Tetrabutyl titanate | Five nitric hydrate bismuths | Fe(NO3)39H2O |
| Take quality (g) | 0.714 | 2.035 | 0.777 |
| Nomenclature of drug | Cobaltous nitrate hexahydrate | Five nitric hydrate erbiums | Five nitric hydrate ytterbiums |
| Take quality (g) | 0.051 | 0.062 | 0.251 |
(2) be that the sodium hydroxide solution of 1.65M dropwise joins in above-mentioned metallic ion mixed liquor by 45mL concentration, whole process is all complete under magnetic stirring, forms uniform suspension.
(3), after suspension being left standstill 8 hours, supernatant liquor is removed, by deionized water and dehydrated alcohol repetitive scrubbing extremely neutrality, dry.
(4) powder 700 DEG C calcining 2 hours are obtained by above-mentioned.
(5) powder is placed in ethanolic soln ultrasonic, gets the solution that is uniformly dispersed, after evaporating solvent, obtain powder.
XRD result shows that sample is monophase materials, and PDF card sequence number is 54-1044, spacer F2mm (42); SEM result shows the morphology microstructure obtained to be diameter is the nanometer ball of about 60-100nm; Under powder room temperature, ferromagnetic property measures (magnetic hysteresis loop), under result shows normal temperature, and the magnetic that the display of this powder is very strong, residual magnetization 2M
r1.66emu/g.Visible light photocatalysis test result shows, irradiate within 4 hours, can degrade 78% rhodamine B.Ultrasonic degradation test result shows, within 4 hours, can degrade 86% rhodamine B.Glow under 980nm laser excitation.Powder dispersion soln and human body HeLa cell cultures 24 hours, result shows that nano particle can by cytophagy, and cell is intact, only has the inhibiting rate of 14%, illustrative material safety non-toxic under 200 μ g/mL.
Table 4:Bi
6er
0.2yb
0.8fe
2.75co
0.25ti
3o
21performance test data
| The phase composite of material thing | Single-phase, PDF card number: 54-1044 |
| Material particle size | 60-100nm |
| Residual magnetization (2M r) | 1.66emu/g |
| Visible light photocatalysis efficiency (4 hours) | 78％ |
| Ultrasonic degradation efficiency (4 hours) | 86％ |
| 980nm stimulated luminescence is composed | Ruddiness, maximum strength 1.27 × 10 5 |
| Inhibiting rate (200 μ g/mL24 hour) | 14％ |
Embodiment 3
(1) 0.843g tetrabutyl titanate is taken, 2.323g five nitric hydrate bismuths, 0.917g Fe(NO3)39H2O, 0.060g Cobaltous nitrate hexahydrate, 0.366g five nitric hydrate erbium, it be 5mL concentration is that in the nitric acid of 4M, magnetic agitation is metallic ion mixed liquor uniformly that 0.074g five nitric hydrate ytterbium is dissolved in volume.
Table 5:Bi
5.8erYb
0.2fe
2.75co
0.25ti
3o
21raw material
| Nomenclature of drug | Tetrabutyl titanate | Five nitric hydrate bismuths | Fe(NO3)39H2O |
| Take quality (g) | 0.843 | 2.323 | 0.917 |
| Nomenclature of drug | Cobaltous nitrate hexahydrate | Five nitric hydrate erbiums | Five nitric hydrate ytterbiums |
| Take quality (g) | 0.060 | 0.366 | 0.074 |
(2) be that the potassium hydroxide solution of 1.8M dropwise joins in above-mentioned metallic ion mixed liquor by 45mL concentration, whole process is all complete under magnetic stirring, forms uniform suspension.
(3), after suspension being left standstill 12 hours, supernatant liquor is removed, by deionized water and dehydrated alcohol repetitive scrubbing extremely neutrality, dry.
(4) powder 750 DEG C calcining 2 hours are obtained by above-mentioned.
(5) powder is placed in ethanolic soln ultrasonic, gets the solution that is uniformly dispersed, after evaporating solvent, obtain powder.
XRD result shows that sample is monophase materials, and PDF card sequence number is 54-1044, spacer F2mm (42); SEM result shows the morphology microstructure obtained to be diameter is the nanometer ball of about 60-100nm; Under powder room temperature, ferromagnetic property measures (magnetic hysteresis loop), under result shows normal temperature, and the magnetic that the display of this powder is very strong, residual magnetization 2M
r1.89emu/g.Visible light photocatalysis test result shows, irradiate within 4 hours, can degrade 81% rhodamine B.Ultrasonic degradation test result shows, within 4 hours, can degrade 89% rhodamine B.Glow under 980nm laser excitation.Powder dispersion soln and human body HeLa cell cultures 24 hours, result shows that nano particle can by cytophagy, and cell is intact, only has the inhibiting rate of 15%, illustrative material safety non-toxic under 200 μ g/mL.
Table 6:Bi
5.8erYb
0.2fe
2.75co
0.25ti
3o
21performance test data
| The phase composite of material thing | Single-phase, PDF card number: 54-1044 |
| Material particle size | 60-100nm |
| Residual magnetization (2M r) | 1.89emu/g |
| Visible light photocatalysis efficiency (4 hours) | 81％ |
| Ultrasonic degradation efficiency (4 hours) | 89％ |
| 980nm stimulated luminescence is composed | Ruddiness, maximum strength 8.62 × 10 5 |
| Inhibiting rate (200 μ g/mL24 hour) | 15％ |
Embodiment 4
(1) 0.696g tetrabutyl titanate is taken, 1.805g five nitric hydrate bismuths, 0.757g Fe(NO3)39H2O, 0.050g Cobaltous nitrate hexahydrate, 0.042g five nitric hydrate erbium, it be 5mL concentration is that in the nitric acid of 4M, magnetic agitation is metallic ion mixed liquor uniformly that 0.429g five nitric hydrate ytterbium is dissolved in volume.
Table 7:Bi
5.46er
0.14y
1.4fe
2.75co
0.25ti
3o
21raw material
| Nomenclature of drug | Tetrabutyl titanate | Five nitric hydrate bismuths | Fe(NO3)39H2O |
| Take quality (g) | 0.696 | 1.805 | 0.757 |
| Nomenclature of drug | Cobaltous nitrate hexahydrate | Five nitric hydrate erbiums | Five nitric hydrate ytterbiums |
| Take quality (g) | 0.050 | 0.042 | 0.429 |
(2) be that the sodium hydroxide solution of 2M dropwise joins in above-mentioned metallic ion mixed liquor by 45mL concentration, whole process is all complete under magnetic stirring, forms uniform suspension.
(3), after suspension being left standstill 16 hours, supernatant liquor is removed, by deionized water and dehydrated alcohol repetitive scrubbing extremely neutrality, dry.
(4) powder 800 DEG C calcining 2 hours are obtained by above-mentioned.
(5) powder is placed in ethanolic soln ultrasonic, gets the solution that is uniformly dispersed, after evaporating solvent, obtain powder.
XRD result shows that sample is monophase materials, and PDF card sequence number is 54-1044, spacer F2mm (42); SEM result shows the morphology microstructure obtained to be diameter is the nanometer ball of about 60-100nm; Under powder room temperature, ferromagnetic property measures (magnetic hysteresis loop), under result shows normal temperature, and the magnetic that the display of this powder is very strong, residual magnetization 2M
r2.0emu/g.Visible light photocatalysis test result shows, irradiate within 4 hours, can degrade 82% rhodamine B.Ultrasonic degradation test result shows, within 4 hours, can degrade 93% rhodamine B.Glow under 980nm laser excitation.Powder dispersion soln and human body HeLa cell cultures 24 hours, result shows that nano particle can by cytophagy, and cell is intact, only has the inhibiting rate of 17%, illustrative material safety non-toxic under 200 μ g/mL.
Table 8:Bi
5.46er
0.14y
1.4fe
2.75co
0.25ti
3o
21performance test data
| The phase composite of material thing | Single-phase, PDF card number: 54-1044 |
| Material particle size | 60-100nm |
| Residual magnetization (2M r) | 2.0emu/g |
| Visible light photocatalysis efficiency (4 hours) | 82％ |
| Ultrasonic degradation efficiency (4 hours) | 91％ |
| 980nm stimulated luminescence is composed | Ruddiness, maximum strength 1.21 × 10 5 |
| Inhibiting rate (200 μ g/mL24 hour) | 17％ |
Embodiment 5
(1) 0.962g tetrabutyl titanate is taken, 2.495g five nitric hydrate bismuths, 1.047g Fe(NO3)39H2O, 0.069g Cobaltous nitrate hexahydrate, 0.585g five nitric hydrate erbium, it be 5mL concentration is that in the nitric acid of 4M, magnetic agitation is metallic ion mixed liquor uniformly that 0.059g five nitric hydrate ytterbium is dissolved in volume.
Table 9:Bi
5.46er
1.4yb
0.14fe
2.75co
0.25ti
3o
21raw material
| Nomenclature of drug | Tetrabutyl titanate | Five nitric hydrate bismuths | Fe(NO3)39H2O |
| Take quality (g) | 0.962 | 2.495 | 1.047 |
| Nomenclature of drug | Cobaltous nitrate hexahydrate | Five nitric hydrate erbiums | Five nitric hydrate ytterbiums |
| Take quality (g) | 0.069 | 0.585 | 0.059 |
(2) be that the sodium hydroxide solution of 1.65M dropwise joins in above-mentioned metallic ion mixed liquor by 45mL concentration, form uniform suspension.
(3), after suspension being left standstill 12 hours, supernatant liquor is removed, by deionized water and dehydrated alcohol repetitive scrubbing extremely neutrality, dry.
(4) powder 700 DEG C calcining 2 hours are obtained by above-mentioned.
(5) powder is placed in ethanolic soln ultrasonic, gets the solution that is uniformly dispersed, after evaporating solvent, obtain powder.
XRD is shown in Fig. 1, and result shows that sample is monophase materials, and PDF card sequence number is 54-1044, spacer F2mm (42); SEM is shown in morphology microstructure that Fig. 2 result shows to obtain to be diameter is the nanometer ball of about 60-100nm; Under powder room temperature, magnetic hysteresis loop is shown in Fig. 3, under result shows normal temperature, and the magnetic that the display of this powder is very strong, residual magnetization 2M
r2.02emu/g.Visible light photocatalysis test result shows, irradiate within 4 hours, can degrade 80% rhodamine B, see Fig. 4.Ultrasonic degradation test result shows, within 4 hours, can degrade 90% rhodamine B, see Fig. 5.Glow under 980nm laser excitation, luminous spectrum is shown in Fig. 6.Powder dispersion soln and human body HeLa cell cultures 24 hours, result shows that nano particle can by cytophagy, and cell is intact, and only have the inhibiting rate of 17% under 200 μ g/mL, illustrative material safety non-toxic, is shown in Fig. 7.
Table 10:Bi
5.46er
1.4yb
0.14fe
2.75co
0.25ti
3o
21performance test data
| The phase composite of material thing | Single-phase, PDF card number: 54-1044 |
| Material particle size | 60-100nm |
| Residual magnetization (2Mr) | 2.02emu/g |
| Visible light photocatalysis efficiency (4 hours) | 80％ |
| Ultrasonic degradation efficiency (4 hours) | 90％ |
| 980nm stimulated luminescence is composed | Ruddiness, maximum strength 1.58 × 10 6 |
| Inhibiting rate (200 μ g/mL24 hour) | 17％ |
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (9)
1. a single phase nano material, it consists of Bi
xer
yyb
zfe
2.75co
0.25ti
3o
21; Wherein
x＝5.46-6.75；
y＝0.05-1.4；
Z=0.14-1.4; And
x+y+z＝7。
2. single phase nano material according to claim 1, wherein said single phase nano material is the powder of nano-scale.
3. single phase nano material according to claim 1, wherein said single phase nano material has magnetic.
4. single phase nano material according to claim 1, described single phase nano material launches ruddiness under infrared ray excited.
5. single phase nano material according to claim 1, described single phase nano material under visible light illumination and/or under hyperacoustic effect by organic substance decomposing.
6. single phase nano material according to claim 1, described single phase nano material can by cytophagy, and lifeless matter toxicity.
7. single phase nano material according to claim 1 is used for the purposes of biomedical magnetic targeted or NMR (Nuclear Magnetic Resonance) imaging.
8. single phase nano material according to claim 1 is used for the purposes of biomedical optical imaging and fluorescent probe.
9. prepare a method for single phase nano material, described method comprises:
By Bi, Er, Yb, Fe, Co, Ti source compound in x: y: z: 2.75: 0.25: 3 ratio be jointly dissolved in after in solvent, with precipitant mix, form suspension, afterwards throw out washed, dry, calcining, obtain and consist of Bi
xer
yyb
zfe
2.75co
0.25ti
3o
21single phase nano material; Wherein
x＝5.46-6.75；
y＝0.05-1.4；
Z=0.14-1.4; And
x+y+z＝7。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410370584.1A CN104098143B (en) | 2014-07-30 | 2014-07-30 | Multifunctional single-phase nano material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410370584.1A CN104098143B (en) | 2014-07-30 | 2014-07-30 | Multifunctional single-phase nano material |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104098143A CN104098143A (en) | 2014-10-15 |
| CN104098143B true CN104098143B (en) | 2015-10-28 |
Family
ID=51666740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410370584.1A Expired - Fee Related CN104098143B (en) | 2014-07-30 | 2014-07-30 | Multifunctional single-phase nano material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104098143B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108558387B (en) * | 2018-01-15 | 2020-10-30 | 信阳师范学院 | Single-phase multi-iron microwave absorbing material and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101077837A (en) * | 2007-05-18 | 2007-11-28 | 中国科学院上海硅酸盐研究所 | Neodymium and vanadium composite doping bismuth titanate powder and preparation method thereof |
| CN102863211A (en) * | 2012-10-10 | 2013-01-09 | 中国科学技术大学 | Titanium-iron-gadolinium cobaltate-bismuth ceramic material in layer structure and preparation method of titanium-iron-gadolinium cobaltate-bismuth ceramic material |
| CN102942361A (en) * | 2012-10-10 | 2013-02-27 | 中国科学技术大学 | Ferrotitanium bismuth cobaltate ceramic material having layered structure and preparation method thereof |
-
2014
- 2014-07-30 CN CN201410370584.1A patent/CN104098143B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101077837A (en) * | 2007-05-18 | 2007-11-28 | 中国科学院上海硅酸盐研究所 | Neodymium and vanadium composite doping bismuth titanate powder and preparation method thereof |
| CN102863211A (en) * | 2012-10-10 | 2013-01-09 | 中国科学技术大学 | Titanium-iron-gadolinium cobaltate-bismuth ceramic material in layer structure and preparation method of titanium-iron-gadolinium cobaltate-bismuth ceramic material |
| CN102942361A (en) * | 2012-10-10 | 2013-02-27 | 中国科学技术大学 | Ferrotitanium bismuth cobaltate ceramic material having layered structure and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104098143A (en) | 2014-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Carofiglio et al. | Doped zinc oxide nanoparticles: synthesis, characterization and potential use in nanomedicine | |
| Du et al. | Hydrothermal synthesis and application of Ho3+-activated NaYbF4 bifunctional upconverting nanoparticles for in vitro cell imaging and latent fingerprint detection | |
| Liu et al. | Controlled synthesis of uniform and monodisperse upconversion core/mesoporous silica shell nanocomposites for bimodal imaging | |
| Chatterjee et al. | Upconversion fluorescence imaging of cells and small animals using lanthanide doped nanocrystals | |
| Das et al. | Gadolinium oxide ultranarrow nanorods as multimodal contrast agents for optical and magnetic resonance imaging | |
| Guo et al. | High-efficiency X-ray luminescence in Eu 3+-activated tungstate nanoprobes for optical imaging through energy transfer sensitization | |
| Yi et al. | PEGylated NaLuF4: Yb/Er upconversion nanophosphors for in vivo synergistic fluorescence/X-ray bioimaging and long-lasting, real-time tracking | |
| Xue et al. | Monodisperse photoluminescent and highly biocompatible bioactive glass nanoparticles for controlled drug delivery and cell imaging | |
| Liu et al. | Multifunctional hydroxyapatite/Na (Y/Gd) F4: Yb3+, Er3+ composite fibers for drug delivery and dual modal imaging | |
| Zhang et al. | Sub-10 nm water-dispersible β-NaGdF4: X% Eu3+ nanoparticles with enhanced biocompatibility for in vivo x-ray luminescence computed tomography | |
| Grzyb et al. | Formation mechanism, structural, and upconversion properties of alkaline rare-earth fluoride nanocrystals doped with Yb3+/Er3+ ions | |
| WO2008048190A1 (en) | Upconversion fluorescent nano-structured material and uses thereof | |
| Luo et al. | A general top-down approach to synthesize rare earth doped-Gd 2 O 3 nanocrystals as dualmodal contrast agents | |
| Zhou et al. | Multifunctional nanocomposite based on halloysite nanotubes for efficient luminescent bioimaging and magnetic resonance imaging | |
| Zhang et al. | Na 0.3 WO 3 nanorods: a multifunctional agent for in vivo dual-model imaging and photothermal therapy of cancer cells | |
| Chen et al. | Multifunctional PVP-Ba2GdF7: Yb3+, Ho3+ coated on Ag nanospheres for bioimaging and tumor photothermal therapy | |
| Li et al. | Preparation and upconversion luminescence cell imaging of O-carboxymethyl chitosan-functionalized NaYF 4: Yb 3+/Tm 3+/Er 3+ nanoparticles | |
| Sui et al. | Integrating photoluminescence, magnetism and thermal conversion for potential photothermal therapy and dual-modal bioimaging | |
| CN103980904A (en) | Lithium yttrium fluoride nanocomposite material, its preparation method, and its application in photodynamic therapy | |
| Hu et al. | Regulation of multifunctional mesoporous core–shell nanoparticles with luminescence and magnetic properties for biomedical applications | |
| Ortega-Berlanga et al. | An overview of gadolinium-based oxide and oxysulfide particles: Synthesis, properties, and biomedical applications | |
| Zhao et al. | Facile fabrication of single-phase multifunctional BaGdF5 nanospheres as drug carriers | |
| Thi Kim Dung et al. | Multispectral emissions of lanthanide-doped gadolinium oxide nanophosphors for cathodoluminescence and near-infrared upconversion/downconversion imaging | |
| Syamchand et al. | The upconversion luminescence and magnetism in Yb 3+/Ho 3+ co-doped LaF 3 nanocrystals for potential bimodal imaging | |
| CN104098143B (en) | Multifunctional single-phase nano material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151028 Termination date: 20210730 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |